Difference between revisions of "Pictilisib (GDC-0941)"
Jump to navigation
Jump to search
m (Jwarner moved page GDC-0941 to Pictilisib (GDC-0941): Generic name available) |
m |
||
Line 3: | Line 3: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
− | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
− | [[Category:PI3K inhibitors]] | + | [[Category:PI3K alpha inhibitors]] |
+ | [[Category:PI3K delta inhibitors]] | ||
[[Category:Investigational]] | [[Category:Investigational]] |
Revision as of 22:04, 16 August 2017
Mechanism of action
From the NCI Drug Dictionary: The orally bioavailable bismesylate salt of a potent small-molecule thieno[3,2-d]pyrimidine inhibitor of the class I phosphatidylinositol 3 kinase (PI3K) isoforms p100alpha and p100delta with potential antineoplastic activity. PI3K inhibitor GDC-0941 selectively binds to PI3K isoforms in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway.